Verrica Pharmaceuticals Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $194.76 million
- Book Value:
- Revenue TTM:
- $8.61 million
- Operating Margin TTM:
- Gross Profit TTM:
- $8.31 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Verrica Pharmaceuticals Inc had its IPO on 2018-06-15 under the ticker symbol VRCA.
The company operates in the Healthcare sector and Biotechnology industry. Verrica Pharmaceuticals Inc has a staff strength of 22 employees.
Shares of Verrica Pharmaceuticals Inc opened at $4.19 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.1 - $4.33, and closed at $4.3.
This is a +2.63% increase from the previous day's closing price.
A total volume of 172,606 shares were traded at the close of the day’s session.
In the last one week, shares of Verrica Pharmaceuticals Inc have slipped by -7.13%.
Verrica Pharmaceuticals Inc's Key Ratios
Verrica Pharmaceuticals Inc has a market cap of $194.76 million, indicating a price to book ratio of 2.8274 and a price to sales ratio of 14.3949.
In the last 12-months Verrica Pharmaceuticals Inc’s revenue was $8.61 million with a gross profit of $8.31 million and an EBITDA of $-22946000. The EBITDA ratio measures Verrica Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Verrica Pharmaceuticals Inc’s operating margin was -272.72% while its return on assets stood at -23.35% with a return of equity of -65.32%.
In Q2, Verrica Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 15%.
Verrica Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.45 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Verrica Pharmaceuticals Inc’s profitability.
Verrica Pharmaceuticals Inc stock is trading at a EV to sales ratio of 9.8963 and a EV to EBITDA ratio of -3.6759. Its price to sales ratio in the trailing 12-months stood at 14.3949.
Verrica Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $62.20 million
- Total Liabilities
- $5.73 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Verrica Pharmaceuticals Inc ended 2023 with $62.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $62.20 million while shareholder equity stood at $55.40 million.
Verrica Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $5.73 million in other current liabilities, 4000.00 in common stock, $-181032000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $55.14 million and cash and short-term investments were $55.14 million. The company’s total short-term debt was $309,000 while long-term debt stood at $0.
Verrica Pharmaceuticals Inc’s total current assets stands at $56.78 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $173000.00 compared to accounts payable of $2.06 million and inventory worth $0.
In 2023, Verrica Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $59000.
Comparatively, Verrica Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Verrica Pharmaceuticals Inc stock is currently trading at $4.3 per share. It touched a 52-week high of $8.695 and a 52-week low of $8.695. Analysts tracking the stock have a 12-month average target price of $12.67.
Its 50-day moving average was $5.38 and 200-day moving average was $5.48 The short ratio stood at 6.81 indicating a short percent outstanding of 0%.
Around 3983.8% of the company’s stock are held by insiders while 3110.2% are held by institutions.
Frequently Asked Questions About Verrica Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. The company’s lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing VP-315, an oncolytic peptide-based injectable therapy for the treatment of dermatology oncologic conditions, including basal cell carcinoma; and cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, including non-metastatic melanoma and non-metastatic Merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.